

MATERIAL SAFETY DATA SHEET

SECTION 1: PRODUCT IDENTIFICATION

PRODUCT NAME:	Triple Antibiotic Ointment <i>bacitracin, neomycin, polymyxin</i>	PRODUCT No.:	51672-2016
----------------------	---	---------------------	-------------------

SECTION 2: PHYSICAL AND CHEMICAL DATA

BOILING POINT:	200°C (392°F)
FREEZING/ MELTING POINT:	58°C (136°F.)
pH:	N/A
Refractive Index at 20°C:	Not indicated.
Viscosity CPS @ 25°C:	Not indicated.
Congeaing Point °F:	Not indicated.
Solubility in Water:	Insoluble.
Solubility in Alcohol:	Practically insoluble.
Solubility in Oil:	Soluble.
Solubility in Other	Most polar solvents.
Specific Gravity (H₂O =1)	0.85 @ 60°C.
% Volatile by Volume	0
Appearance and odor:	A pale, yellow ointment that is odorless.
Evaporation Rate:	0.00 (ether reference).
Vapor pressure (mmHg @ 20° C)	<1 mm.
Vapor density (Air=1)	Not indicated.

SECTION 3: FIRE AND EXPLOSION HAZARD DATA

FLASH POINT (Closed Cup):	390°F, 199°C (97% Petroleum Concentration).
FLAMMABLE LIMITS in Air by Volume:	
Upper Explosion Limit (UEL %):	Not Determined.
Lower Explosion Limit (LEL %):	Not Determined.
AUTO-IGNITION TEMPERATURE (°F):	Not Determined.
EXTINGUISHING MEDIA:	Alcohol foam, dry chemical and carbon dioxide.
SPECIAL FIRE FIGHTING PROCEDURES:	Wear full protective clothing.
UNUSUAL FIRE and EXPLOSION HAZARDS:	May emit toxic fumes.

SECTION 4: REACTIVITY DATA (PHYSICAL HAZARDS)

CHEMICAL STABILITY:	Stable.
HAZARDOUS POLYMERIZATION:	Should not occur.
CONDITIONS TO AVOID:	Not found.
INCOMPATILITY (Material to Avoid):	Extreme heat, sparks, open flame, oxidizers, strong acids and alkalies.
HAZARDOUS POLYMERIZATION:	Should not.
HAZARDOUS DECOMPOSITION PRODUCTS:	May give off fumes of carbon monoxide and carbon dioxide.

SECTION 5: HEALTH HAZARD DATA

Signs and Symptoms of Exposure:

Overexposure	Allergy, kidney and liver impairment, dizziness, incoordination, sensory
Effects:	loss, deafness, nausea, vomiting and diarrhea.
Chronic effects:	May cause allergic reactions in susceptible.
Inhalation:	Not likely due to the physical state of the product.
Eyes:	Use only specified ophthalmic ointment in eyes. Topical ointment will cause eye irritation.
Skin:	Non-toxic under standard application
Ingestion:	May cause kidney, liver and gastrointestinal impairment; may induce dizziness, incoordination, sensory loss and deafness.

SECTION 6: SPECIAL PRECAUTIONS

Precautions To Be Taken In Handling/Storage:	Keep containers closed when not in use. Do not handle or store near heat, flame or oxidizers.
Hygienic Practices:	Wash thoroughly after handling. Use normal hygiene to protect hands, eyes and skin. Use general ventilation to protect your lungs. Do not wear contaminated clothing until thoroughly laundered.

SECTION 7: SPILL/ LEAK PROCEDURES

When materials Is Released Or Spilled:	Assure slippery conditions are nullified. Add sand or dirt. Scoop up and remove. Dispose in accordance with Federal, State and local regulations.
Waste Disposal Methods:	Assure conformity with appliance disposal regulations. Dispose of absorbed material at approved incineration or chemical landfill waste disposal site.

SECTION 8: EMERGENCY AND FIRST AID PROCEDURES

EYES: Flush eyes with copious amounts of water for at least 15 minutes (non-ophthalmic form only).
SKIN: Wash with soap and water.
INGESTION: Induce vomiting. Do not give anything to an unconscious person.

SECTION 9: SPECIAL PROTECTION INFORMATION

Respiratory Protection: General ventilation.
Eye Protection: Normal hygiene.
Skin Protection: Normal hygiene.
Other Protective Clothing or Equipment: As needed to protect repeated/prolonged contact.

SECTION 10: TOXICOLOGICAL INFORMATION

LISTED as a CARCINOGEN:

NTP:	No
IARC:	No
OSHA:	No
OTHER:	N/A

SECTION 11: CONTACT INFORMATION

CONTACT INFORMATION:

Taro Pharmaceuticals U.S.A., Inc.
Attn: Regulatory Affairs Department
3 Skyline Drive
Hawthorne, NY 10532
(914) 345-9001
(914) 593-0078 fax

DISCLAIMER

The above information has been obtained from a number of sources and its accuracy cannot be guaranteed. It is the user's responsibility to evaluate the information and use it in a prudent manner for its particular purpose. Taro Pharmaceuticals assumes no legal responsibility for the use or reliance of this information.

Revised: March 2006